Biopharmaceutical manufacturing faces many new opportunities as we enter this decade. ISPE is returning to Boston for the 2020 ISPE Biopharmaceutical Manufacturing Conference on 1-3 June 2020, bringing you once again an innovative conference, followed by the 2020 ISPE Continuous Manufacturing Workshop and relevant training classes 4-5 June 2020. The Boston area, including Cambridge, is home to over 1,000 biotechnology companies, leading research, and academic institutions advancing biotechnology medicines.
This year, the 2020 ISPE Biopharmaceutical Manufacturing Conference will focus on advances in manufacturing, facilities, and analytics important to bring new therapies to patients. Now more than ever, manufacturing is on the critical path as many new treatments in the area of personalized medicines and individualized batch production present the challenge to bring these medicines through rapid development, reliable manufacturing, and availability to patients a pace with the advances clinical research is bringing to address unmet needs. At the same time, biosimilars are advancing with the opportunity to provide more access to medicines.
Topics that will be addressed at this conference include:
Session leaders and speakers are top leaders and experts in their fields of industry, regulatory, and/or academia. Topics will cover how we continually improve and manufacture our current processes, and continue to advance into new modalities. At the same time, the sessions will address how conventional norms of manufacturing testing and regulatory GMP and CMC oversight are advancing to meet patient needs.
Keep watching as our agenda advances, with updates from our planning committee. I look forward to seeing you in Boston in June.
Through the ISPE Foundation Professional Development Grant program, Silas Tamufor attended the 2023 ISPE Annual Meeting & Expo in October 2023. Tamufor is a PhD student and ISPE Boston Chapter member who began serving as the ISPE Boston Educational Programs Committee Chair in December 2023. He, along with 87 other students and recent graduates, attended the conference thanks to the...
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...